The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Obesity, Insulin Resistance And Hepatocarcinogenesis: Metabolic Mediators And Molecular Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$199,485.00
Summary
Liver cancer (or hepatocellular carcinoma, HCC) is the 3rd most common cause of cancer death, with the incidence in Australia increasing. Recently, it has been shown that obesity, diabetes and fatty liver disease can lead to HCC; this project will explore how metabolic diseases promote HCC. The role of insulin and fatty acids in promoting DNA damage and cell growth will be examined. Understanding how metabolic disease increases HCC risk will improve prevention strategies and possible treatments.
Efficacious Targeting Of Therapeutic Stem Cells To Diseased Livers
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
This project focuses on the challenging area of effective and optimal dosing of stem cell-based therapy for liver diseases. I will investigate the fate and therapeutic effects of natural, surface-modified stem cells and cell-derived vesicles in the body and in liver regions using mathematical models. My key goal is advance cell therapy by providing better dosing and cell engineering strategies.
Therapeutics Discovery Program To Uncover Novel Strategies For Hepatocellular Carcinoma Prevention
Funder
National Health and Medical Research Council
Funding Amount
$396,252.00
Summary
Liver cancer (HCC) incidence is rapidly rising. It is the fastest increasing cause of cancer death in Australia. There are no therapies that prevent HCC or stop liver disease progression. Liver gene profiles have been shown to be associated with HCC development, poor outcome, recurrence, future risk of progressive liver damage and future HCC. Targeting these gene profiles may yield targets for HCC prevention and halt liver disease progression that may revolutionalise liver disease management.